louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04874454: Evaluating Potential Risk of Choking by Laryngeal Ultrasound in Patients With Acute Stroke
Official title: Evaluating Potential Risk of Choking by Laryngeal Ultrasound in Patients With Acute Stroke
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Acute Stroke
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2021-05-05
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The investigators evaluate the vocal cord movement in patients with acute stroke by ultrasound. The occurrence of choking or aspiration pneumonia will be collected in one year after the index stroke.

Detailed description: Post-stroke dysphagia is a common complication for the stroke patient. It may cause aspiration, poor nutrition or even pneumonia; thus, it is crucial for the physicians to evaluate the swallowing function of the stroke patients. However, the evaluation methods nowadays still have some limitations. Water swallowing test is one of the well-known methods, but the test itself would put the patients at risk of aspiration. Furthermore, in order to increase the sensitivity of the water swallowing test, the amount of the water should also be increased; as a consequence, the risk of aspiration will also increase. Fiberoptic endoscopic evaluation of the swallowing and videofluoroscopy have limitations of invasiveness. The laryngeal ultrasound to evaluate the vocal cord movement can be an alternative method, having the characteristics of non-invasiveness and repeat evaluation.

The investigators aim to evaluate the vocal cord movement in patients with acute stroke by ultrasound. The occurrence of choking or aspiration pneumonia will be collected in one year after the index stroke.

Eligibility criteria: Inclusion Criteria:

* acute stroke (in one month) patients

Exclusion Criteria:

* patients with stroke occurring more than one month ago

Primary outcomes:
measure: the incidence of aspiration pneumonia
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Wan-Ching Lien
state: None Selected
Study officials:
affiliation: National Taiwan University Hospital
name: Wan-Ching Lien
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02377154: Comparability of Keratometry of VERION Image Guided System With Established Measuring Devices
Official title: Comparability of Keratometry and Intraocular Lens (IOL) Calculation of VERION Image Guided System With Established Measuring Devices in Ophthalmologically Healthy Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: keratometry
verion
iol
intraocular lens
iolmaster
lenstar
pentacam
IOL calculation
VERION Image Guided System
Lead sponsor: Heidelberg University
Sponsor class: OTHER
First posted: 2015-03-03
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to determine if the keratometric functions of the VERION Image Guided System are comparable to those of established keratometric devices (IOLMaster 500, Pentacam HR, LenStar LS900). Calculated intraocular lenses (IOLs) are compared as a clinical consequence of the biometric measurement for IOLMaster 500, LenStar LS900 and VERION Image Guided System.

In addition the comfort and duration of examination in the different devices is evaluated.


Eligibility criteria: Inclusion Criteria:

* All interested individuals
* Full legal capacity

Exclusion Criteria:

* Pre-existing or actual ocular disease or pathology, history of ocular surgery
* Contact lens wear 2 weeks before examination

Primary outcomes:
measure: Accuracy of repeatability of keratometry as performed by VERION Image Guided System
timeFrame: 3 immediate repetitions at study visit (study consists of 1 visit only)
Secondary outcomes:
measure: Subjective comfort for test persons as evaluated by questionnaire
timeFrame: Immediately after study visit (study consists of 1 visit only)
measure: Duration of measurements of each keratometric device as taken by stopwatch
timeFrame: During measurements from placement of head until completion
measure: Keratometric values as measured by IOLMaster 500, Pentacam HR, LenStar LS900, VERION Image Guided System
timeFrame: At study visit (study consists of 1 visit only)
measure: White-to-White distance as measured by IOLMaster 500, Pentacam HR, LenStar LS900, VERION Image Guided System
timeFrame: At study visit (study consists of 1 visit only)
measure: Intraocular lens calculation as performed by IOLMaster 500, LenStar LS900, VERION Image Guided System
timeFrame: Immediately after measurement
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Department of ophthalmology, University of Heidelberg
state: Baden-Wuerttemberg
Study officials:
affiliation: Department of opthalmology, University of Heidelberg
name: Mike P Holzer, MD, FEBO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03643354: Evaluation of the Prevalence of BPPV and Longterm Effects of Its Therapy Using the Rotundum Device in Retirement Homes
Official title: Evaluation of the Prevalence of BPPV and Longterm Effects of Its Therapy in Retirement Homes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Benign Paroxysmal Positional Vertigo
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2018-08-22
Enrollment: 453
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Benign paroxysmal positional vertigo (BPPV) is one of the most common types of vertigo, especially in elderly. Therefore the investigators have set the goal to evaluate the prevalence of BPPV and its therapy using the Rotundum device in elderly living in retirement homes. Furthermore the investigators use a questionnaire to evaluate possible predictive signs to improve the diagnosis of this disease.


Eligibility criteria: Inclusion Criteria:

* Lives in retirement home/has vertigo/has signed the informed consent

Exclusion Criteria:

* severe heart failure
* untreated cardiac arrythmia
* severe autonomic Dysregulation
* untreated epilepsy
* untreated cervical vertebral body fracture
* inability to follow the test
* weight over 150kg or under 40kg
* height below 140cm or over 200cm
* bedridden
* already participated this study
* participant is connected to the study team

Primary outcomes:
measure: Prevalence of BPPV
timeFrame: Subjects (outcome measure) are assessed during the first 4 Years
Secondary outcomes:
measure: Evaluation of predictive Factors
timeFrame: Is assessed after all subjects have been tested (after 5 Years)
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Stefan Yu Boegli
Study officials:
affiliation: University of Zurich
name: n6iqtwqp Y Bögli
role: PRINCIPAL_INVESTIGATOR
References:
citation: Muller R, Zangger P, Straumann D, Bogli SY. Dizziness and benign paroxysmal positional vertigo among retirement home residents: a cross-sectional descriptive and interventional study. BMC Geriatr. 2022 Feb 12;22(1):120. doi: 10.1186/s12877-022-02818-w.
Clinical trial NCT03164954: Observational Study of an Automatic Detection of Patients at Risk of Chronic Postoperative Pain ("Alerte Douleur")
Official title: Étude Observationnelle Prospective d'Une Alerte Douleur informatisée Automatique Par Les Applications Informatiques hospitalières Des HUG Pour prédire l'Apparition de Douleurs Chroniques Post opératoires
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Pain, Postoperative
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2017-05-24
Enrollment: 355
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: elective surgery

Brief summary: Following surgery, some but not all patients develop persistent (or chronic) postoperative pain CPSP. Several risk factors for this persistent pain have been confirmed in previous studies, but neither surgeons nor anesthesiologists have or take the time to systematically screen patients for this risk. However, hospital information systems often contain the data already, entered during preoperative consultations (e.g. chronic opioid medication) or obtained during the postoperative period (e.g. pain scores).

Here the investigators test an automatic detection algorithm which alerts the analgesia team when a patient at risk of CPSP is or has been operated.

Detailed description: The primary aim of the study is to confirm that the sensitivity of the automatic alert is at least 80%, i.e. that 80% of patients with the primary outcome had an automatic alert.

The secondary aim of the study is to develop an algorithm (combination of risk factors) with which the specificity of the alert can be improved.

Eligibility criteria: Inclusion Criteria:

* 18 years of age
* elective surgery
* perioperative use of the hospital information system
* surgery of the following types: endoprosthesis of the knee or shoulder, amputation other than toe or finger, spinal surgery, cardio-thoracic thoracotomy, laparotomy, inguinal hernia repair, breast surgery

Exclusion Criteria:

* inability to read and understand the consent form or the questionnaires
* emergency surgery
* having already participated in the study for another surgery

Primary outcomes:
measure: CPSP at 6 months
timeFrame: 6 months
Secondary outcomes:
measure: CPSP at 12 months
timeFrame: 12 months
measure: clinically significant pain at 6/12 months
timeFrame: 6/12 months
measure: neuropathic pain at 6/12 months
timeFrame: 6/12 months
measure: acute postoperative pain
timeFrame: 24h postoperative
measure: pain-related functional deficit at 6/12 months
timeFrame: 6/12 months
measure: persistent opioid use
timeFrame: 6/12 months
Other outcomes:
Locations:
city: Genève
country: Switzerland
facility: Hôpitaux Universitaires de Genève
Study officials:
affiliation: University Hospital, Geneva
name: Ali Bourezg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04762654: Turkish Version of Modified Child Dental Anxiety Scale
Official title: Turkish Version of the Faces Version of the Modified Child Dental Anxiety Scale: Evaluation of Validity and Reliability
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Behavior
Child, Only
Anxiety, Dental
Lead sponsor: Recep Tayyip Erdogan University Training and Research Hospital
Sponsor class: OTHER
First posted: 2021-02-21
Enrollment: 300
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: children who presented for the first time to the Faculty of Dentistry in Rize

Brief summary: Background: The faces version of the Modified Child Dental Anxiety Scale (MCDASf) is less time consuming and an easy to understand tool for measuring dental anxiety. The aim of this study was to develop the Turkish version of MCDASf and to analyze its validity and reliability.

Detailed description: The internal consistency reliability was determined by calculating Cronbach's alpha (n=300). Intraclass correlation coefficients (ICCs) were calculated for test-retest reliability (n=67). Construct validity was determined by comparing with the Venham Picture Test (VPT). The factor structure was examined using exploratory factor analysis (EFA). Confirmatory factor analysis (CFA) was used for the dimensionality. The cut-off points of the Turkish version of MCDASf were plotted using a receiver operating characteristic (ROC) curve.

Eligibility criteria: Inclusion Criteria:

* aged between 6-12 years, intellectual sufficiency to complete the questionnaire, and voluntariness to take part in the study. Also, only children whose parents were willing to participate were included

Exclusion Criteria:

* Children who had mental or physical disorders, cooperation problems or dental pain were excluded from the study.

Primary outcomes:
measure: The Turkish version of MCDASf is a reliable scale that meets psychometric properties.
timeFrame: for six months from the beginning of the study
measure: The Turkish version of MCDASf is a valid scale that meets psychometric properties.
timeFrame: for six months from the beginning of the study
Secondary outcomes:
Other outcomes:
Locations:
city: Rize
country: Turkey
facility: Recep Tayyip Erdogan University Training and Research Hospital
city: Rize
country: Turkey
facility: Sema Aydinoğlu
Study officials:
affiliation: Recep Tayyip Erdogan University Training and Research Hospital
name: Ipek Arslan, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05220254: Stanford Tobacco Treatment Services - Virtual Reality Treatment for Smoking Cessation
Official title: Stanford Tobacco Treatment Services - Virtual Reality Treatment for Smoking Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking Cessation
MindCotine Virtual Reality Mindful Exposure Therapy
Keywords: Virtual Reality
Smoking Cessation
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2022-02-02
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study aims to see how feasible a mobile app based virtual reality program for smoking cessation (MindCotine) would be among Stanford cancer center patients


Eligibility criteria: Inclusion Criteria:

* Daily cigarette smoker or some day smoker (\>9 cigarettes per week)
* Age 18+
* English or Spanish fluent
* Smartphone compatibility
* Available to interact with a smartphone app for 6-weeks
* Available to complete the EOT assessment at end of 6-weeks
* Ability to understand and the willingness to personally sign the written IRB-approved informed consent document.
* Confirm phone, email, address during consent

Exclusion Criteria:

* Ever had epilepsy
* Less than 10 cigarettes per week
* Not English or Spanish fluent
* No smartphone compatibility
* Unavailable to interact with the VR program,
* Unavailable to answer questions about the intervention post-treatment

Primary outcomes:
measure: Number of Patients Who Registered With the MindCotine Application
timeFrame: 6 weeks
measure: Number of Patients With Interest in the MindCotine Application
timeFrame: 6 weeks
measure: Number of Patients Who Would Recommend the MindCotine Application as a Measure of Feasibility Among Patients Who Smoke.
timeFrame: 6 weeks
Secondary outcomes:
measure: Number of Patients Who Attempt to Quit Smoking by Using the Application
timeFrame: 6 weeks prior to end of treatment survey
measure: Number of Patients Using Cessation Medication by End of Treatment
timeFrame: 6 weeks
measure: Number of MindCotine App Program Activities Completed
timeFrame: 6 weeks
measure: Number of MindCotine App Journal Entries Completed
timeFrame: 6 weeks
measure: Number of MindCotine App Coaching Engagements Completed
timeFrame: 6 weeks
measure: Average Change in Cigarette Use
timeFrame: baseline to end of treatment, up to 6 weeks
measure: MindCotine Dropout
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University
state: California
Study officials:
References:
Clinical trial NCT06614933: How Does the Type of Waveform Affect Tolerability With Transcutaneous Auricular Vagus Nerve Stimulation?
Official title: How Does the Type of Waveform Affect Tolerability With Transcutaneous Auricular Vagus Nerve Stimulation?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2024-09-26
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The purpose of this research study is to investigate the effects of different forms of a gentle form of electrical stimulation applied to the ear, known as transcutaneous auricular vagus nerve stimulation (taVNS). The research team is interested in how the different forms affect comfort and tolerability, as well as how well it works.


Eligibility criteria: Inclusion Criteria:

1. between the ages of 18-80 years
2. English speaking (must be able to consent and complete the interviews in English)

Exclusion Criteria:

1. chronic pain (average intensity \&gt;2/10 on 0-10 scale, for longer than 3 months)
2. acute pain of intensity greater than 3/10
3. chronic inflammatory conditions that are poorly controlled (e.g., diabetes, autoimmune disease)
4. any unstable medical condition or medical contraindication to moderate physical exertion (e.g., unstable angina or cardiac arrythmia)
5. pregnancy
6. currently taking Buprenorphine or recently stopped taking (within 1 month)
7. presence of cognitive impairment or language barrier that impairs full autonomy in the consent process or in the ability to participate in detailed interviews
8. implants in the head or neck, cochlear implants, or pacemaker
9. head or neck metastasis or recent ear trauma
10. history of epilepsy
11. history of autonomic nervous system dysfunction (e.g., postural orthostatic tachycardia syndrome).

Primary outcomes:
measure: Tolerability measured by tolerability questionnaire
timeFrame: Up to 3 hours.
measure: Tolerability measured by self-report
timeFrame: Up to 3 hours.
Secondary outcomes:
measure: Change in heart rate variability (HRV)
timeFrame: Baseline and up to 3 hours.
Other outcomes:
Locations:
city: Coral Gables
country: United States
facility: University of Miami, Plumer Building
state: Florida
Study officials:
affiliation: University of Miami
name: Marlon Wong, PT, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05218733: Ultrasound Guided Erector Spinae Plane Block vs Intrathecal Morphine
Official title: Postoperative Analgesia in Patients Undergoing Total Abdominal Hysterectomy: A Randomized Controlled Comparison Between Ultrasound Guided Erector Spinae Plane Block and Intrathecal Morphine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Post Operative Pain
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2022-02-01
Enrollment: 120
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Total abdominal hysterectomy (TAH) is a major surgical procedure after which significant post-operative pain and discomfort are anticipated. Abdominal field blocks have been followed for many years and extensively used for pain management following abdominal surgeries such as laparotomies and appendicectomies. Erector Spinae Plane Block (ESPB)-first recently described for the treatment of thoracic neuropathic pain, is a peri-paravertebral regional anesthesia technique that has since been reported as an effective technique for prevention of postoperative pain in various surgeries. Intrathecal opioid administration is an attractive analgesic technique since the opioid is injected directly into the cerebrospinal fluid, close to the structures of the central nervous system where the opioid acts.


Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) 25 to 35kg/m².
* American Society of Anesthesiologist (ASA) physical status I or II.

Exclusion Criteria:

* patient's refusal
* Altered mental status
* Known allergy to study drugs (bupivacaine or morphine)
* Local infection at site of puncture.
* Known case with any pulmonary disease
* Known case with Obstructive sleep apnea (OSA)
* Coagulopathy and /or thrombocytopenia
* Chronic pain
* Severe hepatic or kidney impairment

Primary outcomes:
measure: The time for requirement of first rescue analgesic (min)
timeFrame: 24 hours postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain-Shams University Hospitals
Study officials:
References:
Clinical trial NCT04165733: Professional Quality of Life in German Psychiatrists
Official title: Professional Quality of Life in German Psychiatrists Working with Patients with Mental Disorders
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Mental Disorder
Burnout, Caregiver
Burnout, Professional
Keywords: Professional quality of life
Compassion satisfaction
Burnout
Psychiatrists
Mental disorders
Mental health
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2019-11-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Psychiatrists (already specialzied in psychiatry or currently in specialization for psychiatry) that currently work with patients with mental disorders in Germany.

Brief summary: The purpose of this study is to assess professional quality of life in German psychiatrists working with patients with mental disorders.

Detailed description: The purpose of this study is to assess professional quality of life, which includes compassion satisfaction, burnout and secondary traumatization in psychiatrists, working with patients with mental disorders, in Germany.

Eligibility criteria: Inclusion Criteria:

* Psychiatrits (Physician with specialization in psychiatry or currently in specialization for psychiatry)
* Currently working with patients with mental disorders
* At least 18 years old
* Sufficient German skills for answering the questionnaire

Exclusion Criteria:

None

Primary outcomes:
measure: Compassion Satisfaction
timeFrame: 1 day
measure: Burnout
timeFrame: 1 day
measure: Traumatization
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité Universitätsmedizin Berlin - Department for Psychiatry and Psychotherpy - Charité Campus Mitte
Study officials:
affiliation: Charité Universitätsmedizin Berlin- Charité Campus Mitte - Department for Psychiatry and Psychotherapy
name: Moritz B Petzold, Dipl.-Psych.
role: PRINCIPAL_INVESTIGATOR
References: